ST-Segment Elevation Infarction After TAVR: Problems in Every Aspect

For interventional cardiologists, treating an ST-segment elevation infarction in a patient with transcatheter aortic valve replacement (TAVR) is challenging in many ways. Longer door-to-balloon times and higher rates of primary angioplasty failure than in the general population are translated into very high short- and mid-term mortality.

Infarto con supradesnivel del ST post TAVI: problemas en todos los sentidos

This multicenter study, recently published in JACC, included 118 patients admitted with ST-segment elevation infarction at a mean of 225 days (range: 9 to 680 days) after valvular implantation.

The characteristics of post-TAVR infarction patients who underwent primary angioplasty were compared with 439 patients without prior TAVR who underwent primary angioplasty in the same time period.

The mean door-to-balloon time was higher for TAVR patients (40 minutes vs. 30 minutes [p = 0.003]). Procedure time, fluoroscopy time, radiation dose, and contrast volume were significantly higher for the TAVR population (p < 0.01 for all).

The primary angioplasty failure rate was 4x higher in those with implanted valves (16.5% vs. 3.9%; p < 0.001), including 5 patients whose culprit artery could not be catheterized.

In-hospital mortality was 25.4%, while mid-term mortality (7 months) was as high as 42.4%.

Renal impairment and Killip class >II were 3x more frequent in patients with previous TAVR (hazard ratio [HR]: 3.02; p = 0.004; and HR: 2.74; p = 0.004, respectively).


Read also: New Cardiac Failure Diagnoses after COVID-19 Infection.


All these more frequent events in the TAVR population explain the higher short- and mid-term mortality.

Conclusion

ST-segment elevation infarctions in patients with prior TAVR are associated with much higher short- and mid-term mortality. Longer door-to-balloon times and higher primary angioplasty failure rates are due, partly, to difficulties accessing coronary arteries.

Original Title: ST-Segment Elevation Myocardial Infarction Following Transcatheter Aortic Valve Replacement.

Reference: Laurent Faroux et al. J Am Coll Cardiol. 2021 May 4;77(17):2187-2199. doi: 10.1016/j.jacc.2021.03.014.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....